Sarah brings a deep background in life sciences strategy, development, and commercialization to her role as Chief Operating Officer at EyeBio. Prior to joining EyeBio, Sarah served as Vice President of Translation at Touchlight Genetics where she managed a portfolio of product and platform R&D programs. While at Touchlight Genetics, Sarah led a vaccine clinical development program in partnership with Cancer Research United Kingdom (CRUK) and was part of the fundraising team that saw the company transition into its commercial phase.
Previously, Sarah was a Strategy Consultant on the Life Sciences team at L.E.K. Consulting, where she worked with biotech and pharmaceutical companies on a range of strategy and mergers and acquisition (M&A) projects.
Sarah received a B.Eng. (Hons) in Biomedical Engineering and a B.A. in French and Statistics from the University of Auckland, New Zealand.
